Navigation Links
Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction
Date:3/10/2011

PHILADELPHIA, March 10, 2011 /PRNewswire-USNewswire/ -- Sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, has another possible use -- helping children and young adults with congenital heart disease to better tolerate exercise. Sildenafil significantly improved measures of exercise performance during stress testing in patients with single-ventricle heart disease, according to researchers from The Children's Hospital of Philadelphia.

This study was published online on March 7 in the journal Circulation.  It is the first randomized, double-blind, placebo-controlled, crossover trial to evaluate the impact of sildenafil on measures of exercise performance in children and young adults with single-ventricle heart disease,

All patients involved in the study had earlier undergone the Fontan operation, a procedure that redirects systemic venous blood directly to the pulmonary arteries, bypassing the heart. It is the third operation in a staged series of surgeries for single-ventricle heart defects, life-threatening conditions in which a child is born with severe underdevelopment of one of the pumping chambers of the heart.

"Despite dramatically improved early operative success achieved over the past 20 years, morbidity and mortality are still a challenge for children who have undergone a Fontan operation," said David J. Goldberg, M.D., pediatric cardiologist at The Children's Hospital of Philadelphia and primary investigator of this study. "The staged palliation does not recreate a normal two-ventricle circulation, instead the series of surgeries creates a unique physiology in which exercise capacity is dramatically diminished."

In this study, researchers randomized 28 children and young adults who had undergone the Fontan operation an average of 11 years earlier to receive either placebo or sildenafil three times a day for 6 weeks. After a 6 week break from treatment, subjects were switched to the opposite treatment course.  As a "proof-of-concept" study, the researchers selected a relatively healthy cohort of subjects without significant complications that they felt would have sufficient exercise capacity to complete the study.

The researchers found significant improvements in exercise performance during treatment with sildenafil compared to placebo.  The findings included improved ventilatory efficiency and, in two subgroups of patients, an improved ability to perform moderate levels of exercise. These changes suggest an overall improvement in the physiology associated with this unique circulation.

"The enhanced exercise performance that we found in the study is exciting and may lead to an improvement in day to day activities for these children and young adults," Dr. Goldberg said.  "However, it is important to note that while the results of this study are encouraging, more work is needed to determine whether the short-term benefit found in this study holds up over a longer period of time and whether there are any long-term side effects," he added.

"If the results from this preliminary study are validated in a larger sample over a longer period of time, it may be that this medication has the potential to improve quality of life for patients born with only one ventricle," Dr. Goldberg concluded.

Dr. Goldberg's coauthors were Michael McBride, Ph.D., Bradley Marino, M.D., Nicole Mirarchi, M.D., Brian D. Hanna, M.D., Gil Wernovsky, M.D., Stephen M. Paridon, M.D., and Jack Rychik, M.D., all from The Children's Hospital of Philadelphia; and Benjamin French, M.D., from the University of Pennsylvania School of Medicine.

Grants from The Mark H. and Blanche M. Harrington Foundation and from Big Hearts to Little Hearts provided funding for this study. Dr. Goldberg received support from the NIH T32 grant HL07915.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 460-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.  

Contact: Joey McCool Ryan,  (267) 426-6070, McCool@email.chop.edu


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Exercise and Closing of Overallotment Option
2. EIB Active™ Campaign and Celebrity Nanny Jo Frost Kick Off 2011 in Los Angeles to Educate Families About Asthma and Exercise-Induced Bronchospasm (EIB)
3. Pharmasset Announces Exercise of Underwriters Overallotment Option
4. Amarin Announces Underwriters Exercise of Over-Allotment Option
5. American Council on Exercise (ACE) Announces Nationwide Effort to Eliminate Obesity in America
6. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
7. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
9. BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock
10. Advanced Life Sciences Receives $1.5 Million From Exercise of Unit Warrants and Secures Financing Commitment
11. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/27/2016)... Dublin, CA (PRWEB) , ... June 27, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... illness by protecting their workers from extreme heat at their worksites. Employers ...
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
Breaking Medicine News(10 mins):